JP2015500328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500328A5 JP2015500328A5 JP2014546670A JP2014546670A JP2015500328A5 JP 2015500328 A5 JP2015500328 A5 JP 2015500328A5 JP 2014546670 A JP2014546670 A JP 2014546670A JP 2014546670 A JP2014546670 A JP 2014546670A JP 2015500328 A5 JP2015500328 A5 JP 2015500328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tumor
- brain
- minicells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 229940034982 antineoplastic agent Drugs 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000002158 endotoxin Substances 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000025084 cell cycle arrest Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims description 2
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims description 2
- 108091007460 Long intergenic noncoding RNA Proteins 0.000 claims description 2
- IGLNJRXAVVLDKE-OIOBTWANSA-N Rubidium-82 Chemical compound [82Rb] IGLNJRXAVVLDKE-OIOBTWANSA-N 0.000 claims description 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 2
- FHNFHKCVQCLJFQ-NJFSPNSNSA-N Xenon-133 Chemical compound [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 claims description 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical group [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 claims description 2
- 229940006110 gallium-67 Drugs 0.000 claims description 2
- 229940055742 indium-111 Drugs 0.000 claims description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims description 2
- 229940056501 technetium 99m Drugs 0.000 claims description 2
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 claims description 2
- 229940106670 xenon-133 Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 208000003174 Brain Neoplasms Diseases 0.000 claims 13
- 230000033115 angiogenesis Effects 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 230000001817 pituitary effect Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 241001474374 Blennius Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569907P | 2011-12-13 | 2011-12-13 | |
| US61/569,907 | 2011-12-13 | ||
| PCT/IB2012/002950 WO2013088250A1 (en) | 2011-12-13 | 2012-12-12 | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017158959A Division JP6594383B2 (ja) | 2011-12-13 | 2017-08-22 | 治療薬を脳腫瘍に送達するための細菌由来のインタクトなミニセル |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500328A JP2015500328A (ja) | 2015-01-05 |
| JP2015500328A5 true JP2015500328A5 (enExample) | 2016-02-04 |
| JP6522340B2 JP6522340B2 (ja) | 2019-05-29 |
Family
ID=48611925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546670A Active JP6522340B2 (ja) | 2011-12-13 | 2012-12-12 | 治療薬を脳腫瘍に送達するための細菌由来のインタクトなミニセル |
| JP2017158959A Active JP6594383B2 (ja) | 2011-12-13 | 2017-08-22 | 治療薬を脳腫瘍に送達するための細菌由来のインタクトなミニセル |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017158959A Active JP6594383B2 (ja) | 2011-12-13 | 2017-08-22 | 治療薬を脳腫瘍に送達するための細菌由来のインタクトなミニセル |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9844598B2 (enExample) |
| EP (1) | EP2790668B1 (enExample) |
| JP (2) | JP6522340B2 (enExample) |
| KR (2) | KR20140102294A (enExample) |
| CN (2) | CN104114153A (enExample) |
| AU (2) | AU2012351743B2 (enExample) |
| CA (1) | CA2858315C (enExample) |
| CY (1) | CY1123824T1 (enExample) |
| DK (1) | DK2790668T3 (enExample) |
| ES (1) | ES2843402T3 (enExample) |
| HR (1) | HRP20201930T1 (enExample) |
| HU (1) | HUE052136T2 (enExample) |
| IL (1) | IL233031B (enExample) |
| LT (1) | LT2790668T (enExample) |
| MX (2) | MX385832B (enExample) |
| PT (1) | PT2790668T (enExample) |
| RS (1) | RS61161B1 (enExample) |
| RU (1) | RU2664698C2 (enExample) |
| SG (2) | SG10201601349XA (enExample) |
| SI (1) | SI2790668T1 (enExample) |
| SM (1) | SMT202000676T1 (enExample) |
| TW (1) | TWI627966B (enExample) |
| WO (1) | WO2013088250A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2260874A1 (en) * | 2003-01-06 | 2010-12-15 | Angiochem Inc. | Aprotinin analogs as carriers across the blood-brain barrier |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| PL2279008T3 (pl) | 2008-04-18 | 2020-03-31 | Angiochem Inc. | Kompozycje farmaceutyczne paklitakselu, analogów paklitakselu lub koniugatów paklitakselu oraz powiązane sposoby wytwarzania i zastosowanie |
| EP2346896A4 (en) | 2008-10-15 | 2014-06-25 | Angiochem Inc | ETOPOSID AND DOXORUBICIN CONJUGATES FOR ACTIVITY EXTRACTION |
| MX2011004017A (es) | 2008-10-15 | 2011-06-24 | Angiochem Inc | Conjugados de agonistas glp-1 y usos de los mismos. |
| BRPI0922689A2 (pt) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| EP2421562B1 (en) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| CA2766537A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES2911677T3 (es) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos |
| DK2790668T3 (da) | 2011-12-13 | 2020-11-23 | Engeneic Molecular Delivery Pty Ltd | Bakterielt afledte, intakte miniceller til levering af terapeutiske midler til hjernetumorer |
| MX2014007233A (es) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EA032740B1 (ru) * | 2013-10-04 | 2019-07-31 | Энджинеик Молекьюлар Деливери Пти Лтд | Способ лечения опухоли у индивидуума и набор для осуществления способа |
| US10869926B2 (en) * | 2014-07-15 | 2020-12-22 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| WO2016051389A1 (en) | 2014-10-03 | 2016-04-07 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| PT3394093T (pt) | 2015-12-23 | 2022-05-30 | Modernatx Inc | Métodos de utilização de polinucleotídeos que codificam ligandos ox40 |
| WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| CA3095134A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| DE102018220892A1 (de) * | 2018-12-04 | 2020-06-04 | Robert Bosch Gmbh | Vorrichtung und Verfahren zur Generierung von Labelobjekten für die Umgebung eines Fahrzeugs |
| BR112021011044A2 (pt) * | 2018-12-10 | 2021-08-31 | Flagship Pioneering Innovations Vi, Llc | Sistemas ativos dinâmicos acromossômicos |
| US20220202950A1 (en) * | 2019-05-01 | 2022-06-30 | Engeneic Molecular Delivery Pty Ltd | Compositions comprising bacterially derived intact minicells for theranostic applications |
| CN114641310A (zh) * | 2019-06-21 | 2022-06-17 | 德克萨斯大学系统董事会 | 治疗癌症和其他疾病的靶向α3β1整合素 |
| CN111001014B (zh) * | 2019-12-12 | 2022-04-22 | 四川大学华西医院 | 一种基于固定细菌做载体的抗肿瘤药物及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0222340Y2 (enExample) | 1986-11-18 | 1990-06-15 | ||
| US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| ATE260678T1 (de) | 1999-04-02 | 2004-03-15 | Ct Molecular Med & Immunology | Verfahren zur detektion von endometriosis |
| US6416758B1 (en) | 1999-04-28 | 2002-07-09 | Board Of Regents, The University Of Texax System | Antibody conjugate kits for selectively inhibiting VEGF |
| FR2793684B1 (fr) | 1999-05-17 | 2001-08-10 | Ethypharm Lab Prod Ethiques | Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant |
| US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| US20030203411A1 (en) * | 2001-06-05 | 2003-10-30 | Sabbadini Roger A. | Methods of minicell-based delivery |
| JP4458846B2 (ja) * | 2001-10-15 | 2010-04-28 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏにおけるＤＮＡ導入および遺伝子療法のためのベクターとしての完全なミニ細胞 |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040005700A1 (en) | 2002-05-28 | 2004-01-08 | Surber Mark W. | Poroplasts |
| WO2003101495A1 (en) | 2002-05-29 | 2003-12-11 | Immunomedics, Inc. | Methods and compositions for radioimmunotherapy of brain and cns tumors |
| EP1546203B1 (en) * | 2002-08-01 | 2012-06-20 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| CN1913923B (zh) | 2003-12-09 | 2010-12-08 | 基因分子传递股份有限公司 | 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞 |
| US8772013B2 (en) * | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| NZ549139A (en) * | 2004-02-02 | 2009-11-27 | Engeneic Molecular Delivery Pty Ltd | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| US7837998B2 (en) | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| MX2007002294A (es) * | 2004-08-26 | 2007-10-19 | Engeneic Molecular Delivery Pty Ltd | Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente. |
| US20070065359A1 (en) | 2005-03-14 | 2007-03-22 | Shiladitya Sengupta | Nanocells for diagnosis and treatment of diseases and disorders |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| US9878043B2 (en) * | 2006-06-23 | 2018-01-30 | Engeneic Molecular Delivery Pty Ltd | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| WO2008050255A2 (en) | 2006-10-25 | 2008-05-02 | Koninklijke Philips Electronics N. V. | Contrast agents for detecting prostate cancer |
| AU2008291833B2 (en) | 2007-03-30 | 2012-11-08 | Engeneic Molecular Delivery Pty. Ltd. | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
| KR101623999B1 (ko) * | 2008-06-25 | 2016-05-24 | 벡션 테라퓨틱스 엘엘씨 | 조절된 유전자 자살 메커니즘 조성물 및 방법 |
| KR20110100260A (ko) * | 2008-12-05 | 2011-09-09 | 아브락시스 바이오사이언스, 엘엘씨 | Ｓｐａｒｃ 결합 ｓｃｆｖｓ |
| EA201201435A1 (ru) | 2010-04-20 | 2013-04-30 | Генмаб А/С | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| CA2827443C (en) * | 2011-02-15 | 2021-07-06 | Vaxiion Therapeutics, Inc. | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
| DK2790668T3 (da) | 2011-12-13 | 2020-11-23 | Engeneic Molecular Delivery Pty Ltd | Bakterielt afledte, intakte miniceller til levering af terapeutiske midler til hjernetumorer |
| US11504402B2 (en) | 2018-07-23 | 2022-11-22 | Engenelc Molecular Delivery Pty Ltd | Compositions comprising bacterially derived minicells and methods of using the same |
-
2012
- 2012-12-12 DK DK12857452.2T patent/DK2790668T3/da active
- 2012-12-12 RU RU2014128338A patent/RU2664698C2/ru active
- 2012-12-12 PT PT128574522T patent/PT2790668T/pt unknown
- 2012-12-12 AU AU2012351743A patent/AU2012351743B2/en active Active
- 2012-12-12 SI SI201231862T patent/SI2790668T1/sl unknown
- 2012-12-12 RS RS20201489A patent/RS61161B1/sr unknown
- 2012-12-12 SG SG10201601349XA patent/SG10201601349XA/en unknown
- 2012-12-12 WO PCT/IB2012/002950 patent/WO2013088250A1/en not_active Ceased
- 2012-12-12 SM SM20200676T patent/SMT202000676T1/it unknown
- 2012-12-12 CN CN201280069592.1A patent/CN104114153A/zh active Pending
- 2012-12-12 ES ES12857452T patent/ES2843402T3/es active Active
- 2012-12-12 MX MX2018011664A patent/MX385832B/es unknown
- 2012-12-12 EP EP12857452.2A patent/EP2790668B1/en active Active
- 2012-12-12 SG SG11201403062YA patent/SG11201403062YA/en unknown
- 2012-12-12 HR HRP20201930TT patent/HRP20201930T1/hr unknown
- 2012-12-12 KR KR1020147019228A patent/KR20140102294A/ko not_active Ceased
- 2012-12-12 US US13/711,848 patent/US9844598B2/en active Active
- 2012-12-12 CN CN201811227385.XA patent/CN109125286A/zh active Pending
- 2012-12-12 HU HUE12857452A patent/HUE052136T2/hu unknown
- 2012-12-12 LT LTEP12857452.2T patent/LT2790668T/lt unknown
- 2012-12-12 JP JP2014546670A patent/JP6522340B2/ja active Active
- 2012-12-12 MX MX2014006967A patent/MX359410B/es active IP Right Grant
- 2012-12-12 CA CA2858315A patent/CA2858315C/en active Active
- 2012-12-12 KR KR1020197019600A patent/KR102046042B1/ko active Active
- 2012-12-13 TW TW101147186A patent/TWI627966B/zh active
-
2014
- 2014-06-09 IL IL233031A patent/IL233031B/en active IP Right Grant
-
2017
- 2017-08-22 JP JP2017158959A patent/JP6594383B2/ja active Active
- 2017-10-05 AU AU2017239542A patent/AU2017239542B2/en active Active
- 2017-10-23 US US15/790,885 patent/US10994014B2/en active Active
-
2020
- 2020-11-13 CY CY20201101075T patent/CY1123824T1/el unknown
-
2021
- 2021-03-25 US US17/212,995 patent/US11964021B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500328A5 (enExample) | ||
| Mirzaei et al. | Diagnostic and therapeutic potential of exosomes in cancer: the beginning of a new tale? | |
| Kim et al. | In vivo visualization of endogenous miR-21 using hyaluronic acid-coated graphene oxide for targeted cancer therapy | |
| WO2013088250A4 (en) | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors | |
| Razumilava et al. | miR‐25 targets TNF‐related apoptosis inducing ligand (TRAIL) death receptor‐4 and promotes apoptosis resistance in cholangiocarcinoma | |
| ES2989876T3 (es) | Terapia basada en microARN dirigida contra cánceres positivos para LCP-1 | |
| ES2649165T3 (es) | CD47 terapias dirigidas para el tratamiento de enfermedades infecciosas | |
| US20190024085A1 (en) | Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology | |
| JP2017506074A5 (enExample) | ||
| Scaggiante et al. | Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors | |
| SI2929031T1 (en) | PCSK9 IRNA assemblies and procedures for their use | |
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| JP2015513919A5 (enExample) | ||
| Quirico et al. | Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression | |
| JP2019527563A5 (enExample) | ||
| US20200208157A1 (en) | Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology | |
| Park et al. | Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imaging | |
| Doherty et al. | Aptamers in neuro-oncology: an emerging therapeutic modality | |
| JP2016539623A5 (enExample) | ||
| Ghasemi et al. | Tumor-derived microvesicles: the metastasomes | |
| JP2019506862A5 (enExample) | ||
| JP5667043B2 (ja) | 阻害性オリゴヌクレオチドを送達するための組成物および方法 | |
| Dai et al. | Pancreatic cancer: Nucleic acid drug discovery and targeted therapy | |
| Li et al. | Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer | |
| Rotoli et al. | Advances in oligonucleotide aptamers for NSCLC targeting |